generic imatinib (Novartis)
86
Structured Review
Novartis
generic imatinib
Generic Imatinib, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generic+imatinib/imatinib/10__1200_slash_op___25___01096-98-22-30
Average 86 stars, based on 1 article reviews
Generic Imatinib, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generic+imatinib/imatinib/10__1200_slash_op___25___01096-98-22-30
Average 86 stars, based on 1 article reviews
generic imatinib - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting? Article Snippet: Introduction: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients.. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs.. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or lack of treatment efficacy. Article Title: Benefits and Perils of Generic Drugs for Hematologic Neoplasms and Their Use in Low- and Middle-Income Countries: A Narrative Review Article Snippet: The introduction of generic imatinib following the Adjuvant:Article Title: Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024 Article Snippet: PURPOSE Historically, commercial health plans have applied utilization management (UM) less frequently to oncology treatments than to drugs in other therapeutic areas although this may be changing.. We evaluated trends in UM for oncology therapies from 2017 to 2024, examined variation across health plans and drug characteristics, and assessed evidence sources cited in coverage policies.. METHODS We used the Tufts Medical Center Specialty Drug Evidence and Coverage Database, which contains publicly available coverage policies and cited evidence from 18 large US commercial health plans representing approximately 70% of the market. |